Greenwich LifeSciences, Inc.

NasdaqCM GLSI

Greenwich LifeSciences, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 29,258.97

Greenwich LifeSciences, Inc. Price to Sales Ratio (P/S) is 29,258.97 on January 14, 2025, a 30.96% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Greenwich LifeSciences, Inc. 52-week high Price to Sales Ratio (P/S) is 48,194.77 on March 26, 2024, which is 64.72% above the current Price to Sales Ratio (P/S).
Greenwich LifeSciences, Inc. 52-week low Price to Sales Ratio (P/S) is 19,709.57 on February 13, 2024, which is -32.64% below the current Price to Sales Ratio (P/S).
Greenwich LifeSciences, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 33,159.89.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: GLSI

Greenwich LifeSciences, Inc.

CEO	Mr. Snehal S. Patel
IPO Date	Sept. 25, 2020
Location	United States
Headquarters	Building 14
Employees	3
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Key trends

Past 5 years